We are live on ! Find out more
CPIX icon

Cumberland Pharmaceuticals
CPIX

45 hedge funds and large institutions have $30.1M invested in Cumberland Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less capital invested

Capital invested by funds: $30.2M → $30.1M (-$109K)

4% less funds holding

Funds holding: 47 → 45 (-2)

44% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 16

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
45
Holders Change
-2
Holders Change %
-4.26%
% of All Funds
1.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
9
Reduced
16
Closed
4
Calls
$41K
Puts
–
Net Calls
+$41K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$988K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$550K
3
Norges Bank
Norges Bank
Norway
+$100K
4
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
+$44.7K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$17.9K

Top Sellers

Rank Fund Capital Flow
1
KIM
Kestrel Investment Management
California
-$959K
2
PCM
Perritt Capital Management
Illinois
-$501K
3
Renaissance Technologies
Renaissance Technologies
New York
-$83.9K
4
BIT
BlackRock Institutional Trust
California
-$67.7K
5
Citadel Advisors
Citadel Advisors
Florida
-$65K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$109K -$2.33K -522 -2%
Deutsche Bank
27
Deutsche Bank
Germany
$76K -$1.15K -258 -1%
Wellington Management Group
28
Wellington Management Group
Massachusetts
$75K -$49K -10,980 -40%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$73K +$1.11K +249 +2%
State Street
30
State Street
Massachusetts
$51K -$8.04K -1,800 -14%
DAM
31
Delta Asset Management
Tennessee
$50K – – –
Cambridge Investment Research Advisors
32
Cambridge Investment Research Advisors
Iowa
$45K +$44.7K +10,000 New
WA
33
WealthTrust-Arizona
Arizona
$29K – – –
BA
34
BlackRock Advisors
Delaware
$28K – – –
U
35
UBS
Switzerland
$23K +$4.24K +949 +24%
NFA
36
Nationwide Fund Advisors
Ohio
$17K – – –
Citigroup
37
Citigroup
New York
$14K -$3.09K -692 -18%
OC
38
Oakworth Capital
Alabama
$14K – – –
BIM
39
BlackRock Investment Management
Delaware
$8K +$7.65K +1,714 New
Manulife (Manufacturers Life Insurance)
40
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$5K – – –
PNC Financial Services Group
41
PNC Financial Services Group
Pennsylvania
$5K – – –
BRWM
42
B. Riley Wealth Management
Tennessee
$4K – – –
CCMH
43
Cornerstone Capital Management Holdings
New York
$3K -$19.2K -4,300 -84%
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$297 – – –
PCM
45
Perritt Capital Management
Illinois
– -$501K -111,350 Closed
Citadel Advisors
46
Citadel Advisors
Florida
– -$65K -14,475 Closed
MC
47
Menta Capital
California
– -$57K -12,706 Closed
TRCT
48
Tower Research Capital (TRC)
New York
– -$8K -1,781 Closed
1
2

CPIX Hedge Fund Activity: Q2 2014 in Review

45 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q2 2014, worth a combined $30.1M — down 0.36% from $30.2M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CPIX and 2 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 9 added.

The largest buyer was Millennium Management, adding an estimated $988K. The largest seller was Kestrel Investment Management, cutting an estimated $959K.

  • 45 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q2 2014, down from 47 in Q1 2014.
  • Funds reported $30.1M of Cumberland Pharmaceuticals stock for Q2 2014, down 0.36% quarter-over-quarter.
  • 2 funds opened new Cumberland Pharmaceuticals positions in Q2 2014 and 4 closed out, a net change of -2 holders.
  • The largest Cumberland Pharmaceuticals buyer in Q2 2014 was Millennium Management, an estimated $988K added.
  • The largest Cumberland Pharmaceuticals seller in Q2 2014 was Kestrel Investment Management, an estimated $959K sold.

Based on aggregated 13F filings for Q2 2014.